Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Abiraterone
Drug ID BADD_D00014
Description Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
Indications and Usage Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
Marketing Status Not Available
ATC Code Not Available
DrugBank ID DB05812
KEGG ID Not Available
MeSH ID C089740
PubChem ID 132971
TTD Drug ID D02STN
NDC Product Code 17337-0082; 30007-838; 42291-073; 60687-455; 69238-1165; 42291-024; 69238-1754; 54893-0070
Synonyms abiraterone | 17-(3-pyridyl)androsta-5,16-dien-3beta-ol | CB-7598 | CB 7598 | CB7598
Chemical Information
Molecular Formula C24H31NO
CAS Registry Number 154229-19-3
SMILES CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pneumocystis jirovecii pneumonia22.07.08.009; 11.03.07.0050.000576%Not Available
Medication residue present13.15.01.032--Not Available
Candida infection11.03.03.021--
Multiple organ dysfunction syndrome08.01.03.057--
Anal incontinence17.05.01.021; 07.01.06.029--
Liver function test increased13.03.01.0440.014710%Not Available
Blood aldosterone increased13.10.09.0090.001471%Not Available
Cholangitis acute09.02.01.0060.001471%Not Available
Cystitis radiation20.03.02.009; 12.05.02.0090.001471%Not Available
Full blood count decreased13.01.07.004--Not Available
Metastases to bone16.22.02.005; 15.09.03.0060.015445%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.000576%Not Available
Obstructive uropathy20.01.05.0040.002206%Not Available
Penile size reduced21.12.01.0180.001471%Not Available
Pernicious anaemia10.04.01.007; 07.17.01.004; 01.03.01.0030.001471%Not Available
Prostate cancer recurrent21.04.02.008; 16.25.01.0050.000576%Not Available
Prostate cancer stage IV21.04.02.010; 16.25.01.0070.000576%Not Available
Prostatic specific antigen decreased13.22.01.0020.003677%Not Available
Urinary bladder haemorrhage24.07.01.086; 20.03.01.0230.001471%Not Available
Terminal state08.01.03.0790.000384%Not Available
Metastases to bone marrow16.22.02.013; 01.05.01.0220.002942%Not Available
Metastases to meninges17.02.10.012; 16.22.02.0030.000384%Not Available
Pulmonary sepsis22.07.01.014; 11.01.11.0140.000384%Not Available
Meningorrhagia17.08.01.056; 12.01.10.016; 24.07.04.0300.000576%Not Available
Lymphangiosis carcinomatosa24.09.02.007; 16.22.02.009; 01.09.01.0270.000576%Not Available
Clostridium difficile infection11.02.02.009--Not Available
Prostatic specific antigen abnormal13.22.01.0150.007355%Not Available
Pancreatic carcinoma stage IV16.13.10.005; 07.21.09.0080.000384%Not Available
Communication disorder19.19.01.0080.001471%Not Available
Sarcopenia15.05.06.0040.000384%Not Available
The 21th Page    First    Pre   21 22    Next   Last    Total 22 Pages